A Study of IBI363 in Subjects With Advanced Melanoma | MicrobiomeTrials← Back to trialsNCT06081920
A Study of IBI363 in Subjects With Advanced Melanoma
RecruitingPHASE2INTERVENTIONAL
Trial Details
Start: 2023-10-19Est. Completion: 2028-10-19
Enrollment target: 180 participants Locations- Beijing Cancer Hospital, Beijing, Beijing Municipality, China
- Peking University Cancer Hospital & Institute, Beijing, China,, Beijing, Beijing Municipality, China
- Fujian Cancer Hospital, Fuzhou, Fujian, China
- The Third people's hospital of Zhengzhou, Zhengzhou, Henan, China
- Hunan Cancer Hospital, Changsha, Hunan, China
- Nanjing Drum Tower Hospital, Nanjing, Jiangsu, China
- The first affiliated hospital of Nanchang university, Nanchang, Jiangxi, China
- Jilin Cancer Hospital, Changchun, Jilin, China
- The first hospital of Jilin University, Changchun, Jilin, China
- Qilu Hospital of Shandong university, Jinan, Shandong, China
- Shanxi Bethune Hospital, Taiyuan, Shanxi, China
- Yunan Cancer Hospital, Kunming, Yunan, China
Other microbiome trials you might be interested in
MelanomaGliomaThyroid CancerNon-Small Cell Lung CancerMalignant NeoplasmsBrain NeoplasmsAdvanced or Metastatic Solid TumorsHGGLGGLow Grade GliomaHigh Grade GliomaDifferentiated Thyroid CancerNSCLC (Non-small Cell Lung Cancer)
The purpose of this clinical trial is to learn the safety and effects of the study medicine (PF-07799544) alone or in co…
Birmingham, United StatesEst. completion Aug 2, 2027
Main Objective of this study is to examine long-term safety of nivolumab monotherapy including combinations and other ca…
Huntsville, United StatesEst. completion Aug 25, 2029